SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.980
+0.180 (4.74%)
At close: Dec 5, 2025, 4:00 PM EST
3.900
-0.080 (-2.01%)
After-hours: Dec 5, 2025, 7:57 PM EST
SAB Biotherapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '25 Dec 5, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 189 | 35 | 63 | 30 | 340 | - | |
| Market Cap Growth | 533.64% | -44.79% | 113.36% | -91.25% | - | - | |
| Enterprise Value | 85 | 9 | 66 | 27 | 336 | - | |
| Last Close Price | 3.98 | 3.79 | 6.88 | 5.90 | 78.10 | - | |
| PS Ratio | 1651.95 | 26.48 | 28.33 | 1.24 | 5.58 | - | |
| PB Ratio | 1.15 | 1.35 | 1.11 | 0.96 | 8.81 | - | |
| P/TBV Ratio | 1.15 | 1.35 | 1.11 | 0.96 | 8.81 | - | |
| P/OCF Ratio | - | - | - | - | 170.89 | - | |
| EV/Sales Ratio | 739.18 | 6.91 | 29.32 | 1.14 | 5.51 | - | |
| Debt / Equity Ratio | 0.04 | 0.18 | 0.10 | 0.19 | 0.22 | 0.21 | |
| Debt / EBITDA Ratio | - | - | - | - | - | 0.38 | |
| Asset Turnover | 0.00 | 0.02 | 0.03 | 0.36 | 0.88 | 1.48 | |
| Quick Ratio | 10.33 | 2.61 | 5.23 | 1.37 | 1.56 | 3.00 | |
| Current Ratio | 10.50 | 2.98 | 5.45 | 1.47 | 1.90 | 3.12 | |
| Return on Equity (ROE) | 18.56% | -81.92% | -95.51% | -53.85% | -44.21% | 86.15% | |
| Return on Assets (ROA) | -22.76% | -41.86% | -35.30% | -27.37% | -12.16% | 34.47% | |
| Return on Capital (ROIC) | -25.39% | -57.16% | -47.50% | -43.00% | -17.77% | 41.14% | |
| Return on Capital Employed (ROCE) | -25.00% | -118.50% | -52.10% | -80.50% | -24.50% | 45.20% | |
| Earnings Yield | -2.26% | -97.39% | -66.52% | -63.04% | -5.05% | - | |
| FCF Yield | -19.84% | -98.89% | -39.91% | -86.20% | -2.64% | - | |
| Buyback Yield / Dilution | -11.66% | -67.74% | -26.86% | -59.20% | -1.21% | 23.30% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.